Gynecology & Obstetrics
Open Access
ISSN: 2161-0932
ISSN: 2161-0932
Z. Nene and P Soma-Pillay
Accepted Abstracts: Pediatr Therapeut
Aim: To determine the correlation between the warfarin dose and maternal and fetal outcomes in pregnant women with prosthetic heart valves who followed a local anticoagulation protocol. Th ese patients received obstetric care at the Steve Biko Academic hospital, a tertiary referral hospital in Pretoria, South Africa, from January 2005 to August 2009. Methods: A retrospective observational study of pregnancy outcome in women with mechanical heart valves who received the following anticoagulation protocol: Unfractionated subcutaneous heparin (UFH) twice daily that was titrated to a therapeutic partial thromboplastin time (PTT), given when possible from pregnancy detection until 12 weeks gestation followed by warfarin from weeks 12-35 (target INR of 2.5 ? 3.5) then UFH until elective caesarean section (CS) at 38 weeks with the morning dose of UFH withheld pre-operatively. Results: Sixty-two pregnancies were managed during the study period. Fift y-one women had mitral valve prostheses, 2 had aortic and 9 patients had double valve prostheses. Th e mean gestational age at booking was 16 weeks. Forty-one women booked aft er the fi rst trimester and were exposed to warfarin during the teratogenic period. Fift een patients resided in Pretoria, 13 patients were referred from outside Pretoria but within the Gauteng Province and 34 patients were from other provinces. Fetal outcome: Th ere were 5 cases of warfarin embryopathy. In 2 of these cases maternal warfarin use was 5mg or less in the fi rst trimester. In the remainder of the pregnancies, fetal outcome was analysed in 3 groups depending on the maternal dose of warfarin. In group 1(n=26) the maternal warfarin dose was 5mg or less; group 2 (n=20) ? 5.1mg-7.4mg and 7.5mg or more in group 3 (n=11). Th e live birth rate was 64%, 60% and 45% respectively in each group. Th ere was no diff erence in birth weight between the 3 groups. Th ere were 8 (35%) miscarriages in group 1, 5 (25%) in group 2 and 1 (9%) miscarriage in group 3. Th e stillbirth rate in each group was 3.8%, 15% and 36% respectively (p = 0.012). Maternal outcome: Th ere were no maternal deaths or cases of valve thrombosis. Th ere were 6 (9.7%) near misses. Four mothers developed cardiac failure and were treated medically. Th ere were 2 cases of bleeding problems post-caesarean section requiring massive blood transfusions and re-look laparotomies. Conclusion: In this study warfarin in pregnancy is associated with a low risk of valve thrombosis or maternal death. Fetal outcome is dependant on the maternal warfarin dose. However if pregnancy continues past 25 weeks the risk of stillbirth is signifi cantly lower if the warfarin dose is 5mg compared to higher doses.